Long-term consequences of the delay between virologic failure of highly active antiretroviral therapy and regimen modification

Objectives:Current treatment guidelines recommend immediate modification of antiretroviral therapy in HIV-infected individuals with incomplete viral suppression. These recommendations have not been tested in observational studies or large randomized trials. We evaluated the consequences of delayed modification following virologic failure. Design/methods:We used prospective data from two clinical cohorts to estimate the effect of time until regimen modification following first regimen failure on all-cause mortality. The impact of regimen type was also assessed. As the effect of delayed switching can be confounded if patients with a poor prognosis modify therapy earlier than those with a good prognosis, we used a statistical methodology – marginal structural models – to control for time-dependent confounding. Results:A total of 982 patients contributed 3414 person-years of follow-up following first regimen failure. Delay until treatment modification was associated with an elevated hazard of all-cause mortality among patients failing a reverse transcriptase inhibitor-based regimen (hazard ratio per additional 3 months delay = 1.23, 95% confidence interval: 1.08, 1.40), but appeared to have a small protective effect among patients failing a protease inhibitor-based regimen (hazard ratio per additional 3 months delay = 0.93, 95% confidence interval: 0.87, 0.99). Conclusion:Delay in modification after failure of regimens that do not contain a protease inhibitor is associated with increased mortality. Protease inhibitor-based regimens are less dependent on early versus delayed switching strategies. Efforts should be made to minimize delay until treatment modification in resource-poor regions, where the majority of patients are starting reverse transcriptase inhibitor-based regimens and HIV RNA monitoring may not be available.

[1]  R. Elston,et al.  Minimizing Resistance Consequences After Virologic Failure on Initial Combination Therapy: A Systematic Overview , 2006, Journal of acquired immune deficiency syndromes.

[2]  C. Katlama,et al.  The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial , 2006, The Lancet.

[3]  J. Robins,et al.  Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. , 2000, Epidemiology.

[4]  Mark J van der Laan,et al.  Deletion/Substitution/Addition Algorithm in Learning with Applications in Genomics , 2004, Statistical applications in genetics and molecular biology.

[5]  M. Kazatchkine,et al.  Long-term clinical outcome of human immunodeficiency virus-infected patients with discordant immunologic and virologic responses to a protease inhibitor-containing regimen. , 2001, The Journal of infectious diseases.

[6]  B. Chi,et al.  Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. , 2006, JAMA.

[7]  P. Harrigan,et al.  Adherence–resistance relationships for protease and non-nucleoside reverse transcriptase inhibitors explained by virological fitness , 2006, AIDS.

[8]  Christopher D Pilcher,et al.  Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. , 2006, JAMA.

[9]  M. Davidian,et al.  Marginal structural models for analyzing causal effects of time-dependent treatments: an application in perinatal epidemiology. , 2004, American journal of epidemiology.

[10]  M. Kozal,et al.  A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial , 2006, The Lancet.

[11]  T. Wrin,et al.  CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. , 2002, The Journal of infectious diseases.

[12]  J. Robins,et al.  Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures , 2002, Statistics in medicine.

[13]  R Hoh,et al.  Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. , 2001, The New England journal of medicine.

[14]  J. Eron,et al.  Triple-class antiretroviral drug resistance: risk and predictors among HIV-1-infected patients , 2007, AIDS.

[15]  R. Stone,et al.  Discordant Responses to Potent Antiretroviral Treatment in Previously Naive HIV-1-Infected Adults Initiating Treatment in Resource-Constrained Countries: The Antiretroviral Therapy in Low-Income Countries (ART-LINC) Collaboration , 2007, Journal of acquired immune deficiency syndromes.

[16]  P. Harrigan,et al.  Emergence of Drug Resistance Is Associated with an Increased Risk of Death among Patients First Starting HAART , 2006, PLoS medicine.

[17]  S. Gove,et al.  The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings , 2006, The Lancet.

[18]  Jeffrey N. Martin,et al.  Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia , 2002, AIDS.

[19]  John W. Mellors,et al.  Panel on Clinical Practices for Treatment of HIV Infection , 2000 .

[20]  J. Robins,et al.  Marginal Structural Models and Causal Inference in Epidemiology , 2000, Epidemiology.

[21]  N. Ford,et al.  HIV viral load monitoring in resource-limited regions: optional or necessary? , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  A. Telenti,et al.  Emergence of HIV-1 drug resistance in previously untreated patients initiating combination antiretroviral treatment: a comparison of different regimen types. , 2007, Archives of internal medicine.

[23]  Robert T. Schooley,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. U.S. Department of Health and Human Services (DHHS). , 1997, BETA : bulletin of experimental treatments for AIDS : a publication of the San Francisco AIDS Foundation.

[24]  Bruno Ledergerber,et al.  Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.

[25]  Eoin Coakley,et al.  Rate of viral evolution and risk of losing future drug options in heavily pretreated, HIV-infected patients who continue to receive a stable, partially suppressive treatment regimen. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[26]  Michael S Saag,et al.  Treatment for Adult HIV Infection 2006 Recommendations of the International AIDS Society–USA Panel , 2006 .

[27]  Martin S. Hirsch,et al.  Treatment for adult HIV infection. , 2004 .

[28]  S. Cole,et al.  Use of a marginal structural model to determine the effect of aspirin on cardiovascular mortality in the Physicians' Health Study. , 2002, American journal of epidemiology.

[29]  R. D’Aquila,et al.  Effect of Persistent Moderate Viremia on Disease Progression During HIV Therapy , 2004, Journal of acquired immune deficiency syndromes.

[30]  A. Hsu,et al.  Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. , 2004, The Journal of infectious diseases.

[31]  N. Ford,et al.  Scaling up antiretroviral treatment in resource-poor settings , 2006, The Lancet.

[32]  M. Hirsch,et al.  Monitoring HIV treatment in developing countries , 2006, BMJ : British Medical Journal.

[33]  Jonathan AC Sterne,et al.  Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.